ESTRO 2020 Abstract book

S540 ESTRO 2020

Conclusion Apart from the IM vessels, the MWT does not cover the IM volumes. If the indication to treat the IM is strong and particularly in the case of positive IM, accurate contouring and contour based planning as well as advanced techniques should be used. PO-0926 Derma-QOL after heparinoid moisturizer for radiation damage in breast-conserving surgery patients J. Kawamori 1 , T. Itasawa 2 , S. Fukushima 3 , R. Ito 2 , C. Haga 2 , H. Yamauchi 4 , K. Sekiguchi 5 1 St Luke International Hospital, Department of Radiation Oncology, Tokyo, Japan ; 2 St Luke’s International Hospital, Department of Radiation Oncology, Tokyo, Japan ; 3 Kumagai Clinic, Radiology, Tokyo, Japan ; 4 St Luke’s International Hospital, Department of Breast Surgery, Tokyo, Japan ; 5 Sonodakai Radiation Oncology Clinic, Radiation Oncology, Tokyo, Japan Purpose or Objective The aim of this study was to evaluate the effect of heparinoid (HP) moisturizer use on quality of life (QOL) in patients with acute radiation skin damage after breast- conserving surgery (BCT-RT). Additional analysis was performed on the effect of dosimetric factors. Material and Methods A randomized controlled trial of a moisturizer group (Group M) and a no-moisturizer group (Group C) to examine whether HP application as moisturizer contributed to improvements in QOL among patients with radiation skin reaction to BCT-RT. A total of 75 patients who received BCT-RT between October 2017 and September 2018 were randomly allocated in our hospital to Group M and Group C. Group M applied HP from the radiation start date twice daily for 7 weeks. QOL was assessed using the Dermatology Life Quality Index (DLQI) at the radiation start date and at Weeks 1, 2, 3, 4, 5 and 7 after the radiation start date. A higher DLQI score indicates a worse quality of life. Radiation treatment was whole-breast irradiation (42.56 Gy in 16 fractions), with added tumor bed boost (10-15 Gy in 4-6 fractions) in 17 cases, according to our hospital protocol. Twenty cases were planned using the field in field method, 52 cases were by tangential breast IMRT. Results 72 cases were analyzed (Group M, 35 cases; Group C, 37 cases). The mean (± standard deviation) DLQI total scores 4 weeks after the start date was 2.063±2.169 in Group M, and 2.233±2.161 in Group C. No significant difference between M and C groups was seen (Mann-Whitney U test, p=0.894). In both groups, the DLQI total score showed no significant change until 2 weeks after the start date, and significantly worsened from 3 weeks to 5 weeks after the start date (Figure 1). No significant difference was seen between groups at 7 weeks after the start date. The difference of DLQI total score tended to be greater in high D max cases from 3 weeks to 5 weeks after the start date . In group C, the difference of DLQI total score was 0.5 in cases with D max <45Gy and 2.313 in cases with D max ≥45Gy, at 4 weeks after the start date (Shapiro-Wilk test, Student- t test p<0.05). In group M, the difference of DLQI total score was 1.25 in cases with D max <45Gy, 1.25 in cases with D max ≥45Gy, at 4 weeks after the start date (Figure 2).

Conclusion In terms of DLQI total score, no significant improvement was obtained from moisturizer application 4 weeks after the start of radiation. However, 4 weeks after the start date, the change of DLQI total score was improved by moisturizer application in high D max cases. PO-0927 Assessing the Quality of Care in Breast Cancer Radiotherapy S. Vinod 1 , S. Pyun 2 , J. Shafiq 3 , K. Chiew 4 , A. Bece 5 , R. Martin 6 , J. De Leon 7 1 Liverpool Hospital, Cancer Therapy Centre, Liverpool BC, Australia ; 2 University of New South Wales, School of Medical Sciences, Sydney, Australia ; 3 Ingham Institute of Applied Medical Research, Collaboration for Cancer Outcomes Research and Evaluation CCORE, Liverpool, Australia ; 4 Liverpool Hospital, Cancer Therapy Centre, Liverpool, Australia ; 5 St George Hospital, St George Cancer Care Centre, Kogarah, Australia ; 6 Prince of Wales Hospital, Nelune Comprehensive Cancer Centre, Randwick, Australia ; 7 Wollongong Hospital, Illawarra Cancer Care Centre, Wollongong, Australia Structured quality assurance programs through measurement of quality indicators (QIs) are vital for assessing quality of care provided by health care systems with the goal of improving patient outcomes. Radiotherapy (RT) is an essential component of multidisciplinary management of breast cancer patients. The aims of this study were to identify published QIs relevant to breast cancer RT, assess the feasibility of measuring these from routine clinical information and evaluate the proportion of patients whose care met published benchmarks. This abstract has been withdrawn Purpose or Objective Purpose